STTK

Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs, Inc. (STTK) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -8.1
EV / EBITDA -4.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -37.1%
Price Return 12M 142.2%
Catalyst Signal 0.00
Market Cap $473.6M
TTM Revenue $0.0
Price / Sales N/A
ROE -47.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D+ (1.7) C- (2.1) C (2.5) C+ (2.6) C (2.3)
2026-11-08 F (0.6) D+ (1.6) C- (2.1) C (2.4) C+ (2.6) D+ (1.8)
2026-11-01 F (0.3) D+ (1.6) C- (2.1) C+ (2.6) C+ (2.7) D+ (1.8)
2026-10-25 F (0.3) D+ (1.6) C- (2.1) C (2.3) C+ (2.6) D+ (1.8)
2026-10-18 F (0.4) D+ (1.6) C- (2.1) C (2.2) C+ (2.6) D+ (1.8)
Page 1 of 3